Product Description
Mechanisms of Action: GDF8 Binder
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Muscular Dystrophy, Duchenne
Phase 1: Healthy Volunteers|Muscular Atrophy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| A031-03 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2011-06-01 |
|
| A031-06 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2011-05-01 |
|
| A031-02 | P1 |
Completed |
Muscular Atrophy |
2011-02-01 |
|
| A031-01 | P1 |
Completed |
Healthy Volunteers |
2009-07-01 |